Lamirax

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lamirax

Quick Facts

Property Description
Active ingredient Lamotrigine
Form Oral tablets (standard, dispersible, extended-release)
Pharmacological class Anticonvulsant (AED) / Mood Stabilizer
Route of administration Oral (by mouth)
Origin Synthetic Phenyltriazine derivative

What Type of Medicine is Lamirax?

Lamirax is a synthetic, prescription-only medication containing the active substance Lamotrigine, which is broadly classified as an Anticonvulsant (Antiepileptic Drug, or AED). The drug is chemically identified as a unique phenyltriazine derivative, distinguishing its structure within the pharmacological landscape.

This classification is significant because Lamirax is also clinically recognized for its dual capacity as a mood stabilizer, a key attribute utilized in the maintenance treatment of mood disorders in adults. This dual function is supported by pharmacological studies detailing the drug's action on neuronal stability.

Composition and Available Preparations

The composition of Lamirax is a single-active-ingredient product featuring only Lamotrigine alongside standard inactive components necessary for its solid oral dosage. The medication is intended strictly for oral administration. Lamirax is prepared in several essential forms, including the standard tablet, the chewable or dispersible tablet (which facilitates easier administration), and the specialized extended-release tablet. The extended-release option is designed to provide a gradual, sustained delivery of the active substance over a prolonged period, supporting consistent therapeutic concentrations for chronic needs.

General Purpose and High-Level Action

The general purpose of Lamirax is to help restore balance to neural communication by suppressing abnormal, excessive electrical activity in the brain. Lamotrigine achieves this primarily by stabilizing nerve cell membranes, which prevents rapid, repeated electrical firing, and by modulating the release of key excitatory chemical messengers like glutamate. This fundamental action controls disorganized neurological signaling, providing a core therapeutic benefit for stabilizing overall neural function in conditions characterized by such imbalances.

Regulatory References

  1. FDA Lamotrigine Label
  2. FDA Lamotrigine Label - Administration
  3. FDA Lamotrigine Mechanism of Action

What side effects are possible with Lamirax?

Possible Side Effects and Safety Information

The safety profile of Lamirax (Lamotrigine) is defined by officially documented adverse reactions categorized by frequency and the physiological systems affected. Regulatory documents specify risks for certain reactions, particularly those related to the skin and dose management.

Frequency-Classified Adverse Reactions

Adverse effects are grouped based on their occurrence rate in clinical trials, as classified in regulatory sources:

Classification Examples of Reactions
Very Common (ge 1/10) Headache, dizziness, blurred vision, nausea, and rash.
Common (ge 1/100 to < 1/10) Ataxia (impaired coordination), somnolence (drowsiness), tremor, fatigue, and diarrhea.

Serious Adverse Reactions and Safety Patterns

The most serious safety concerns explicitly highlighted in regulatory labeling are Severe Cutaneous Adverse Reactions (SCARs). This category includes Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Blood disorders, such as neutropenia and agranulocytosis, and Hemophagocytic lymphohistiocytosis (HLH) are also documented as rare but serious possibilities.

Time-related safety patterns indicate that the risk of SCARs is highest during the initial weeks of treatment and is increased by rapid dose escalation. Safety considerations for special populations note that the incidence of serious rash is observed to be higher in the pediatric population compared to adults.

Overdose and Emergency Response

Overdose and when to seek help

The following information is based strictly on official government regulatory documents (e.g., FDA, EMA equivalent prescribing information).

Feature Official Regulatory Statement
Documented Overdose Presentations Symptoms include Central Nervous System (CNS) effects such as ataxia, dizziness, somnolence, slurred speech, and nystagmus. Severe presentations can lead to profound CNS depression, coma, and paradoxical increased seizures or status epilepticus.
Physiological Systems Affected Severe outcomes are documented for the CNS and the Cardiovascular system. Cardiac risk includes cardiac conduction delays (e.g., QRS complex prolongation), ventricular arrhythmias, and cardiac arrest (reported in postmarketing experience).
Dose-Related Factors Exceeding the recommended initial dose or the rate of dose escalation is a factor associated with an increased risk of severe, potentially fatal serious rashes (SJS/TEN) and Multiorgan Hypersensitivity Reactions (DRESS).

When Immediate Medical Help is Required

The regulatory guidance necessitates immediate medical attention and admission to hospital for a suspected overdose due to the risk of life-threatening complications. Urgent help is mandatory for the appearance of cardiac symptoms, loss of consciousness/coma, or seizures.

Management is symptomatic and supportive, as no specific pharmacological antidote is known. Hospital monitoring, including ECG monitoring, is required to manage the documented risk of cardiac conduction abnormalities.

Therapeutic Uses of Lamirax

The therapeutic applications of Lamirax (Lamotrigine) are generally focused on supporting stability across neurological and psychiatric domains.


Lamirax is commonly used to help manage symptoms associated with certain seizure types and for the long-term stabilization of mood in adults. The primary therapeutic domains commonly addressed include: epilepsy, severe seizure disorders like Lennox-Gastaut syndrome, and the maintenance treatment of Bipolar I Disorder.

Control of Partial and Generalized Seizures

Lamirax is applied across domains where additional symptomatic support is needed in conditions such as epilepsy. It is used for managing symptoms that create noticeable physiological strain, and may assist with managing the frequency and intensity of various seizure types, including focal seizures and primary generalized tonic-clonic seizures. This provides supportive relief that helps patients cope more steadily with symptom fluctuations and assists with maintaining functional stability.

Maintenance Treatment for Bipolar Mood Swings

For Bipolar I Disorder, Lamirax is considered relevant in clinical settings that involve recurrent or episodic manifestations. It is commonly used as a long-term treatment (maintenance therapy) to help manage the symptomatic domain of mood cycling. This supports the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort during symptomatic periods.


Quick Fact: Therapeutic Applications
Lamirax is commonly used to help manage both the physiological strain of seizures and the recurrent, episodic manifestations of major mood swings, supporting functional stability in both contexts.

Eligibility and Restrictions for Use

Lamirax (lamotrigine) eligibility is determined by specific regulatory criteria concerning age, indication, history of severe reactions, and underlying health status.

Contraindicated Populations

Use is absolutely contraindicated for individuals with known hypersensitivity to lamotrigine or any components of the tablet. The medicine should ordinarily be discontinued and not re-initiated in patients who previously stopped treatment due to a serious rash associated with its use.

Age and Indication Limitations

Age Group Eligibility Status (Regulatory Labeling)
Children (Under 2 years) Not recommended for adjunctive epilepsy therapy; safety/efficacy not established.
Adults (18+ years) Eligible for maintenance treatment of Bipolar I Disorder.
Pediatrics (Under 18) Effectiveness for Bipolar I maintenance not established.

Condition-Based Restrictions

Patients with moderate or severe hepatic impairment or significant renal functional impairment are restricted populations who require caution and likely necessitate official dosage adjustments as outlined in prescribing information. The expected benefit must be carefully weighed against the risk of serious arrhythmias for patients with certain underlying cardiac disorders.

Pregnancy and Lactation

Lamirax is a restricted use medication during pregnancy, often requiring specialist monitoring due to the potential for fetal harm shown in animal data. The drug is present in breast milk, and use during lactation should be monitored, with monitoring of the infant for adverse effects.

What should I know about interactions with other medicines?

Lamirax (Lamotrigine) is primarily cleared from the body through glucuronidation, making it subject to numerous documented pharmacokinetic interactions with other products that affect this pathway.

Documented Interactions Modifying Lamirax Exposure

Co-administered Product Official Effect on Lamirax Concentration Mechanistic Statement
Valproate Increases concentrations by more than 2-fold Inhibition of glucuronidation
Carbamazepine, Phenytoin, Phenobarbital, Primidone, Rifampin Decreases concentrations by approximately 40% Induction of glucuronidation
Estrogen-containing Oral Contraceptives Decreases concentrations by approximately 50% Induction of glucuronidation
Lopinavir/ritonavir Decreases exposure by approximately 50% Induction of glucuronidation
Atazanavir/lopinavir Decreases exposure by approximately 32% Induction of glucuronidation

Other Officially Noted Constraints

  • Transporter Restriction: Coadministration with Organic Cationic Transporter 2 (OCT2) substrates with a narrow therapeutic index is not recommended by regulatory agencies.
  • Pharmacodynamic Risk: Coadministration with Valproate is associated with an increased risk of severe rash.
  • Timing Condition: Lamirax concentrations may rise, even double, during the hormone-free interval of estrogen-containing oral contraceptives.
  • Population Note: Patients with Liver Impairment (moderate and severe) may experience decreased clearance of Lamirax, requiring consideration for its systemic exposure. Lamirax may also exhibit additive CNS depressant effects with alcohol.

Mechanism of Action

Lamirax (Lamotrigine) operates by targeting fundamental drivers of excessive electrical and chemical signaling in the central nervous system (CNS) through molecular and cellular mechanisms.


Selective Blockade of Voltage-Gated Sodium Channels

The drug's primary mechanism is the voltage-dependent blockade of Voltage-Gated Sodium Channels (VGSCs). Lamirax preferentially binds to these channels in their inactive state—the conformation adopted after rapid firing—thereby suppressing the neuron’s capacity for sustained high-frequency repetitive firing (SFRF). This action reflects the drug's selective binding to channels in the inactive state, rather than those operating during resting membrane potentials.


Attenuating Excitatory Neurotransmitter Release

The membrane stabilization resulting from VGSC blockade initiates a critical mechanistic cascade: it reduces the influx of calcium ions required for synaptic vesicle fusion. This action ultimately modulates, or decreases, the presynaptic release of the excitatory neurotransmitter, Glutamate. This mechanism limits the overall excitatory chemical load in the synapse, contributing to the dampening of neural activity initiated at the electrical level.


Physiological Consequence: Reduced Neuronal Excitability

The combined effects—controlling the electrical impulse by blocking sodium channels and limiting the chemical signal by reducing glutamate release—result in the dampening of disorganized neurological activity. This core physiological change reflects a maintained state of reduced neuronal excitability.

Dosage and Administration Information

Lamirax (lamotrigine) is approved for oral administration and is supplied in multiple forms, including standard, dispersible, and extended-release tablets. The administration protocol is defined by a strict, gradual schedule to introduce the medicine into the body and establish a stable concentration for long-term use.

Dosing and Titration Protocol

Adult administration begins with a mandatory slow dose titration phase that spans several weeks. For non-interacting regimens, the initial dose is typically 25 mg once daily for the first two weeks. The complete escalation schedule is highly dependent on the use of concomitant medications; for example, dosing is slower when taken with valproate and faster when taken with enzyme-inducing drugs.

The maintenance dose, which is the long-term therapeutic amount, generally falls in the range of 100 mg to 200 mg per day for bipolar I maintenance, and may reach 300 mg to 500 mg per day for certain epilepsy regimens. Standard tablets are typically taken in divided daily doses, while extended-release tablets are taken once a day.

Administration Requirements

Lamirax may be taken with or without food. The dispersible tablets are designed to be swallowed whole, chewed, or dispersed in a small volume of liquid. Importantly, the extended-release tablets must be swallowed whole and must not be crushed or cut, as this violates the mechanism that controls the sustained delivery of the drug.

Specific dosage reductions are officially required for patients with moderate-to-severe hepatic impairment. If multiple doses are missed, the original slow titration schedule may need to be re-initiated. Should the medicine be discontinued, the dosage must be gradually reduced over a minimum of two weeks.

Recent Clinical Evidence

Research evidence / Overview of studies for Lamirax

Evidence for Maintenance Treatment in Bipolar I Disorder

Research exploring the substance's role related to maintenance treatment in Bipolar I Disorder has been conducted. These studies primarily utilized intermediate- to long-term Randomized Controlled Trials (RCTs). Researchers examined adults with Bipolar I Disorder, and the main outcome studied was the time until the recurrence or new emergence of any mood episode (depressive, manic, hypomanic, or mixed).

Findings describe patterns observed in the studies where the time until the occurrence of a depressive episode was generally longer for patients receiving the study substance compared to those receiving placebo. However, evidence quality varies across studies when examining outcomes related to the prevention of manic or hypomanic episodes. Certainty remains low for outcomes capturing phases of heightened symptom activity (mania), and there is limited information for long-term outcomes beyond the typical one-year study periods.


Evidence for Seizure Control in Epilepsy

The substance was studied for its application in various seizure disorders. The evidence base comes largely from short-term, placebo-controlled Randomized Controlled Trials where research examined the substance's use in an adjunctive treatment context, meaning patients were already taking other anti-epileptic medications.

Research examined both adults and pediatric patients (age 2 and older) experiencing focal seizures. Outcomes related to systemic or functional imbalance were primarily measured by monitoring the percentage change in the frequency of focal seizures from the start of the study. Data show patterns related to changes in seizure frequency that were observed during the study period compared to placebo.

Adjunctive Use for Lennox-Gastaut Syndrome

Specific controlled trials were conducted to study the substance as an adjunctive treatment for individuals with Lennox-Gastaut Syndrome (LGS). Studies monitored outcomes describing episodic or acute changes by measuring the frequency of major generalized seizures. Findings describe patterns observed in the studies that indicated changes in seizure frequency over the short-term treatment intervals (typically 16 weeks).


Evidence Gaps and Areas of Uncertainty

The research landscape highlights what is known — and what is still uncertain. One key limitation is that evidence quality varies across studies, particularly concerning the Bipolar I indication. Furthermore, long-term effects are not fully established, as follow-up durations were limited across many pivotal trials for both mood and seizure indications. Subgroup findings are uncertain, and research provides context but not individual predictions, as research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Lamirax (FAQ)

Q: How quickly should I expect to notice any effects from Lamirax?

Lamirax is introduced into the body through a slow dose titration schedule that lasts several weeks. This gradual process is necessary to safely establish a stable, long-term concentration of the substance. Therefore, therapeutic effects are generally not expected to be noticeable immediately.

Q: Does Lamirax need to build up in the system to start working?

Yes, the official treatment protocol is designed to gradually escalate the dose over a period of weeks. This titration process is essential to introduce the medicine gradually and establish the stable concentration needed for it to work effectively for its intended long-term use.

Q: Does Lamirax interact with common pain relievers like ibuprofen or acetaminophen?

According to official drug labeling, there is no known pharmacokinetic interaction documented between the active substance and common over-the-counter pain relievers such as ibuprofen (an NSAID) or acetaminophen.

Q: Are there any known issues with taking Lamirax and birth control pills?

Official documents state that estrogen-containing oral contraceptives can significantly decrease the concentration of Lamirax in the bloodstream by about 50%. The concentration of Lamirax may also temporarily rise during the inactive or hormone-free interval of the pill cycle.

Q: Is it okay to stop taking Lamirax suddenly, or must it be tapered?

Official labeling states the dosage should be gradually reduced over a minimum period of two weeks if the medicine is discontinued. This gradual reduction is required because stopping suddenly may be associated with an increased risk of seizure frequency.

Q: What kind of studies were performed to get Lamirax approved?

Regulatory approval was supported by evidence derived from multiple Randomized Controlled Trials (RCTs). These included short-term, placebo-controlled studies focused on seizure control and intermediate- to long-term studies examining its use for Bipolar I maintenance treatment.

Q: Is Lamirax a controlled substance in the US or other countries?

Lamirax is a prescription-only medication, but it is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or equivalent regulatory bodies.

Q: Does Lamirax have any documented interactions with alcohol?

Official warnings indicate that Lamirax may exhibit additive central nervous system (CNS) depressant effects when combined with alcohol. The combined use is noted to potentially increase central nervous system depressant effects.

Q: Does Lamirax need to be refrigerated, or how should it be stored?

Regulatory requirements state that Lamirax must be stored at Controlled Room Temperature, generally around 25 C (77 F). It should be kept in its original container, protected from light and excessive moisture. Refrigeration is not listed as a storage requirement.

Q: Can Lamirax be split, crushed, or chewed?

Whether the tablet can be altered depends on the formulation. Extended-release tablets must be swallowed whole because crushing or cutting them can disrupt the controlled-release feature of the medication. However, standard and dispersible tablets may typically be swallowed whole, chewed, or dispersed in a small amount of liquid.

Q: What is the half-life of Lamirax described as in official documents?

The elimination half-life, which is the time it takes for half of the substance to be cleared from the system, is typically described as 25 to 33 hours in adults. It is noted in official documents that this time can be altered significantly depending on whether the individual is taking other interacting medications.

Q: If I miss a dose of Lamirax, does that affect how well it works long-term?

The official dosing protocol states that if multiple doses are missed, the original slow dose titration schedule may need to be re-initiated. This re-initiation is often suggested to minimize the serious risk of developing a severe rash.

Q: Does Lamirax cause weight gain or weight loss?

Official regulatory labeling does not list weight gain or weight loss among its frequently reported or medically serious side effects.

Q: Is it common for Lamirax to cause fatigue or sleepiness?

Official documents list somnolence (drowsiness) and fatigue as Common side effects. This means that based on clinical trials, these effects occurred in ge 1% to < 10% of people using the medication.

Q: How long does Lamirax typically stay in your system after stopping it?

Clearance time can vary for each person, but based on the typical adult half-life of 25 to 33 hours, the active substance can take several days to a week to be substantially cleared from the body. This clearance time is also affected by whether other interacting medicines are being taken.

Q: Will taking Lamirax affect my ability to drive or operate machinery?

Official patient counseling information advises that this medicine may cause effects such as dizziness, drowsiness, and blurred vision. Caution is therefore advised when operating machinery or driving until you understand how the medication affects you.

Q: Can Lamirax be taken at the same time as common supplements like vitamins?

Official labeling does not generally specify interactions with common vitamins or nutritional supplements.

Q: Can a patient with diabetes use Lamirax safely?

According to official regulatory documents, diabetes is not listed as a specific contraindication or restriction on who can or cannot use the medicine.

Q: Is there a generic version of Lamirax available?

Yes, the active substance, which is lamotrigine, is widely available in the United States and internationally as a generic formulation.

Q: What is the difference between Lamirax and its active ingredient?

Lamirax is the brand name given to the product by its manufacturer. The term lamotrigine refers to the active ingredient itself, which is the substance responsible for the medication’s effects. Lamotrigine is the generic name.

Q: Can Lamirax worsen existing mental health conditions like anxiety?

Regulatory warnings note that the medicine carries a documented risk of increasing suicidal thoughts or behavior in a small number of patients, particularly during early treatment.

Q: Is there a maximum time frame for how long Lamirax can be taken?

Official regulatory documents do not define a maximum duration for how long the substance can be taken. However, studies noted that the long-term effects beyond the typical one-year duration of pivotal clinical trials are areas where further data collection is needed.

Q: Do older adults require a different dosage description for Lamirax?

Official labeling states that no specific dosage adjustment is required for geriatric patients based solely on age. However, regulatory documents advise caution when selecting the initial dose, accounting for potential reduced clearance in this population.

Q: What is the official statement regarding Lamirax and breastfeeding?

Official guidance confirms that the active substance is present in breast milk. If used during lactation, careful monitoring of the infant is recommended for possible adverse effects, such as increased drowsiness, rash, or difficulties with feeding.

Q: Can Lamirax affect the results of lab tests, like blood work?

The medicine has been associated with rare blood disorders that can be detectable during laboratory testing. Monitoring the concentration of the substance itself also involves blood tests.

Q: Does Lamirax affect the immune system in any way?

Yes, official documents describe a rare but serious reaction called Hemophagocytic lymphohistiocytosis (HLH) as a risk. This condition involves the excessive activation of the body's infection-fighting immune system.

Q: Is it described anywhere that Lamirax can cause changes in vision?

Yes, official safety information lists blurred vision as a Very Common side effect, meaning it occurred in 1 out of 10 or more people in clinical trials.

Q: Is there official information on whether Lamirax causes hair loss?

Official regulatory labeling does not list hair loss (alopecia) among its frequently reported or medically serious side effects.

Q: Can Lamirax be taken if a person is fasting for medical reasons?

Official administration guidelines state that the medicine may be taken with or without food. This general guidance suggests that a person who is temporarily fasting for medical reasons should still be able to adhere to their required dosing schedule.

How should Lamirax be stored and disposed of?

Official Storage and Disposal Requirements

Lamirax (lamotrigine) must be stored according to specific, regulated requirements to maintain its chemical stability and quality.

Requirement Official Regulatory Statement
Storage Temperature Store at Controlled Room Temperature, typically 25 C (77 F), with permitted excursions up to 30 C (86 F) [Source: FDA/NIH].
Environmental Protection Keep the medication in a dry place, protected from light and excessive heat [Source: NIH/Health Canada].
Container Integrity Keep the container tightly closed and store the product in its original packaging [Source: Health Canada].
Child Safety All medicine must be kept out of the reach and sight of children [Source: FDA/NIH].

Disposal Instructions

Disposal must adhere to pharmaceutical waste guidelines. Unused or expired Lamirax should be managed through an official drug take-back program or by returning it to a pharmacist to minimize environmental risk. Disposal into household trash or wastewater is discouraged by regulatory bodies [Source: EMA/FDA].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lamirax found in:

A-Z Index: